JunHe Assists Alphamab Oncology in its Listing on M88 Malaysia Main Board of M88 Malaysia SEHK

On December 12, 2019, Alphamab Oncology was listed on M88 Malaysia main board of M88 Malaysia Hong Kong Stock Exchange, with M88 Malaysia stock code 9966. Alphamab Oncology issued 179, 403, 000 shares with an issuing price of HK .2 per share. M88 Malaysia amount of funds raised was about HK .83 billion (approximately USD 230 million).

Alphamab Oncology is a leading clinical stage biopharmaceutical company with a fully integrated biological preparation platform. By using protein engineering it can target four highly differentiated tumor candidates, each of which are in M88 Malaysia clinical stage of testing. M88 Malaysia proteins include KN046, a BsAb immunocheckpoint inhibitor, and PD-L1 and CTLA-4. KN026, a new type of tumor immunizing agent, can combine with HER2 BsAb and KN019. KN019 is an immunosuppressive fusion protein based on CTLA-4, which is widely used in autoimmune disorders and tumor M88 Malaysiarapy. KN035 may be M88 Malaysia first subcutaneous PD-L1 inhibitor in M88 Malaysia world.

As M88 Malaysia company’s Chinese legal advisor, we assisted in solving M88 Malaysia legal problems involved in M88 Malaysia reorganization and listing of M88 Malaysia company prior to its listing on M88 Malaysia SEHK. This included reviewing and revising M88 Malaysia various transaction documents, and replying in detail to M88 Malaysia Hong Kong SEHK and M88 Malaysia SFC. This was in order to prove that M88 Malaysia company met M88 Malaysia various requirements of M88 Malaysia SEHK's core products and patents concerning unprofitable biotech enterprises. JunHe’s Intellectual Property team provided professional patent due diligence services regarding M88 Malaysia complicated patents of M88 Malaysia company, including M88 Malaysia FTO investigation of M88 Malaysia company’s multiple core products. JunHe’s IP team analyzed M88 Malaysia independent intellectual property rights owned by M88 Malaysia company for several of its core products, and reviewed and sorted out a series of IP transfer and license agreements. Alphamab Oncology and oM88 Malaysiar intermediaries held M88 Malaysia solid work attitude and professionalism of JunHe's team in high regard.

M88 Malaysia leading partner of this project was. M88 Malaysia undertaking partner wasM88 Game 在私募股权投资领域, and M88 Malaysia leading partner for patent due diligence wasm88 casino review Perkins.